Abstract Background Serotonergic psychedelics have recently re-emerged as promising therapeutic agents in psychiatry, showing positive outcomes in clinical trials for treatment-resistant depression, major depression, and PTSD. However, their effects on the immune system are poorly characterized. It remains unclear whether these compounds exert immunomodulatory effects that contribute to their...
Classical serotonergic psychedelics, such as psilocybin, show emerging evidence of therapeutic potential across a range of mental health disorders, including depression, anxiety, and substance use disorders, with indications of transdiagnostic efficacy. While early-phase studies yielded encouraging results, recent larger-scale phase 3 trials, such as those evaluating psilocybin for...
By synthesising findings from both clinical and preclinical research, this review aims to provide an understanding of the interplay between 5-HT2A receptor psychedelics and the immune system and considers how their immunomodulatory effects associate with neuronal and behavioural changes. A PubMed literature search covering the past 30 years was conducted using keywords such as "5-HT2A...